Latest Asx Disclosures News

333D Limited reported a 12% increase in quarterly cash receipts from digital asset management contracts, maintaining steady cash flow despite slight operating cash usage. The company’s annual contract revenue surpassed $970,000, reflecting growing traction in healthcare digital services.

Raptis Group Limited has confirmed that director James Raptis will resign effective 30 September 2025, affirming the company’s compliance with ASX continuous disclosure rules.

Kingsland Minerals has withdrawn its previously implied production target for the Leliyn Graphite Project’s processing plant, citing non-compliance with ASX disclosure rules and advising investors to disregard prior estimates.

Biome Australia Limited has confirmed its record FY25 sales revenue of approximately $18.4 million, marking a 41% increase year-on-year, while affirming full compliance with ASX continuous disclosure rules.

ENRG Elements Limited has confirmed the materiality of recent director resignations and appointments, clarifying timing and compliance with ASX disclosure rules.

Cygnus Metals has clarified that its recent share price and volume spike stemmed from new assay results at its Golden Eye prospect and broader copper sector dynamics, confirming compliance with ASX disclosure rules.

Locate Technologies has secured $1.45 million through a share placement and established a $2 million At-the-Market facility to boost financial flexibility, while unveiling a strategic plan to hold Bitcoin as part of its treasury management.

Nufarm Limited confirms its half-year earnings align closely with analyst expectations despite a late-stage $16 million inventory valuation adjustment. The company maintains compliance with ASX disclosure rules amid market scrutiny.

Heavy Minerals Limited attributes its recent share price jump to media coverage about its upcoming Port Gregory Pre-Feasibility Study and confirms compliance with ASX disclosure rules.

Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.

Mayne Pharma Group has acknowledged a delayed filing of a director's interest notice due to administrative oversight and is taking steps to reinforce compliance with ASX disclosure rules.

Tivan Limited has responded to ASX inquiries about a social media post by its executive chair concerning fluorite exploration, affirming compliance with disclosure rules and pending assay results.